Biodesix (BDSX) Total Current Liabilities (2019 - 2026)

Biodesix has reported Total Current Liabilities for 8 years, with the latest figure at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 8.81% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (up 8.81% YoY), and the FY2025 full-year result was $17.4 million, up 21.79% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $14.5 million, down from $17.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $37.4 million in Q3 2022, with the low at $13.0 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $23.2 million across 5 years, with a median of $22.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 84.89% — and 2024, when it plunged 60.3%.
• Biodesix's Total Current Liabilities stood at $22.8 million in 2022, then soared by 46.31% to $33.4 million in 2023, then plunged by 57.16% to $14.3 million in 2024, then gained by 21.79% to $17.4 million in 2025, then fell by 16.9% to $14.5 million in 2026.
• The last three Total Current Liabilities figures came in at $14.5 million (Q1 2026), $17.4 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.